Evaluation of TRIM63 RNA in situ hybridization (RNA-ISH) as a potential biomarker for alveolar soft-part sarcoma (ASPS)
Medical Oncology · 2024
DOI: 10.1007/s12032-024-02305-9 ↗Kurz gefasst
Fachartikel in der Zeitschrift Medical Oncology, 2024. Verfasst von Alexander S Taylor und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, University of Michigan Medical School, 2800 Plymouth Road, Building 35, Ann Arbor, MI, 48109, USA. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, RNA, Sarcoma, Alveolar Soft Part, Tripartite Motif Proteins. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Alveolar soft-part sarcoma (ASPS) is a rare soft tissue tumor with a broad morphologic differential diagnosis. While histology and immunohistochemistry can be suggestive, diagnosis often requires exclusion of other entities followed by confirmatory molecular analysis for its characteristic ASPSCR1-TFE3 fusion. Current stain-based biomarkers (such as immunohistochemistry for cathepsin K and TFE3) show relatively high sensitivity but may lack specificity, often showing staining in multiple other entities under diagnostic consideration. Given the discovery of RNA in situ hybridization (RNA-ISH) for TRIM63 as a sensitive and specific marker of MiTF-family aberration renal cell carcinomas, we sought to evaluate its utility in the workup of ASPS. TRIM63 RNA-ISH demonstrated high levels (H-score greater than 200) of expression in 19/20 (95%) cases of ASPS (average H-score 330) and was weak or negative in cases of paraganglioma, clear cell sarcoma, rhabdomyosarcoma, malignant epithelioid hemangioendothelioma, as well as hepatocellular and adrenal cortical carcinomas. Staining was also identified in tumors with known subsets characterized by TFE3 alterations such as perivascular epithelioid cell neoplasm (PEComa, average H-score 228), while tumors known to exhibit overexpression of TFE3 protein without cytogenetic alterations, such as melanoma and granular cell tumor, generally showed less TRIM63 ISH staining (average H-scores 147 and 96, respectively). Quantitative assessment of TRIM63 staining by RNA-ISH is potentially a helpful biomarker for tumors with molecular TFE3 alterations such as ASPS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, University of Michigan Medical School, 2800 Plymouth Road, Building 35, Ann Arbor, MI, 48109, USA.
- Michigan Center for Translational Pathology, Ann Arbor, MI, USA.
- Rogel Cancer Center, Michigan Medicine, Ann Arbor, MI, USA.
- Department of Urology, University of Michigan Medical School, Ann Arbor, MI, USA.
- Howard Hughes Medical Institute, Ann Arbor, MI, USA.
- Department of Pathology, University of Michigan Medical School, 2800 Plymouth Road, Building 35, Ann Arbor, MI, 48109, USA. xminwang@med.umich.edu.
Zitieren
APA
Taylor, A. S., Mannan, R., Pantanowitz, L., Chinnaiyan, A. M., Dhanasekaran, S. M., Hrycaj, S., Cao, X., Chan, M. P., Lucas, D., Wang, X. M., & Mehra, R. (2024). Evaluation of TRIM63 RNA in situ hybridization (RNA-ISH) as a potential biomarker for alveolar soft-part sarcoma (ASPS). Medical Oncology. https://doi.org/10.1007/s12032-024-02305-9
Vancouver
Taylor AS, Mannan R, Pantanowitz L, Chinnaiyan AM, Dhanasekaran SM, Hrycaj S, et al. Evaluation of TRIM63 RNA in situ hybridization (RNA-ISH) as a potential biomarker for alveolar soft-part sarcoma (ASPS). Medical Oncology. 2024. doi:10.1007/s12032-024-02305-9
BibTeX
@article{Taylor2024,
author = {Taylor, Alexander S and Mannan, Rahul and Pantanowitz, Liron and Chinnaiyan, Arul M and Dhanasekaran, Saravana M and Hrycaj, Steven and Cao, Xuhong and Chan, May P and Lucas, David and Wang, Xiao-Ming and Mehra, Rohit},
title = {Evaluation of TRIM63 RNA in situ hybridization (RNA-ISH) as a potential biomarker for alveolar soft-part sarcoma (ASPS)},
journal = {Medical Oncology},
year = {2024},
doi = {10.1007/s12032-024-02305-9}
}
EUVIMED